Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer
K Miyazaki, S Sato, T Kodama… - Molecular and …, 2016 - spandidos-publications.com
This retrospective study was conducted to evaluate whether oral acid suppressant (AS)
therapy is associated with decreased efficacy of gefitinib and erlotinib, particularly in patients …
therapy is associated with decreased efficacy of gefitinib and erlotinib, particularly in patients …
Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non–small-cell lung cancer harboring …
Y Zenke, K Yoh, S Matsumoto, S Umemura, S Niho… - Clinical Lung Cancer, 2016 - Elsevier
Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …
Clinical impact of gastric acid suppressants use on the efficacy of gefitinib in patients with advanced adenocarcinoma of the lung harboring common egfr mutations
WC Kwok, JC Man Ho, DC Leung Lam… - Clinical Cancer …, 2020 - ingentaconnect.com
Background: Gefitinib was approved by the Food and Drug Administration (FDA) of the
United States (US) for the treatment of advanced non-small cell carcinoma harboring …
United States (US) for the treatment of advanced non-small cell carcinoma harboring …
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) …
JW Neal, HA Wakelee, JL Feliciano, SB Goldberg… - 2014 - ascopubs.org
8088 Background: Erlotinib (E) is widely used in the treatment of advanced EGFR mutant
NSCLC, with a historical progression free survival of about 9 months. Preclinical data …
NSCLC, with a historical progression free survival of about 9 months. Preclinical data …
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
X Song, Z Wang - OncoTargets and therapy, 2017 - Taylor & Francis
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as a standard
therapy have been used in EGFR-mutated adenocarcinoma of non-small-cell lung cancer …
therapy have been used in EGFR-mutated adenocarcinoma of non-small-cell lung cancer …
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
K Azuma, M Nishio, H Hayashi, K Kiura… - Cancer …, 2018 - Wiley Online Library
Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of
East Asian patients with non‐small‐cell lung cancer (NSCLC) and confer sensitivity to …
East Asian patients with non‐small‐cell lung cancer (NSCLC) and confer sensitivity to …
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
M Wen, J Xia, Y Sun, X Wang, X Fu… - … : Targets and Therapy, 2018 - Taylor & Francis
Purpose Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer …
chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer
M Takeda, K Nakagawa - Molecular and Clinical …, 2017 - spandidos-publications.com
Recent progress in the research on the molecular biology of lung cancer revealed that the
clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort… - ERJ Open …, 2022 - Eur Respiratory Soc
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
相关搜索
- lung cancer acid suppressants
- efficacy of tyrosine kinase inhibitors
- effect of acid suppressants
- lung cancer clinical impact
- lung cancer egfr mutations
- lung cancer gefitinib in patients
- lung cancer medication use
- intercalated tki tyrosine kinase
- lung cancer toxicity profile
- gastric acid suppressants
- efficacy of gefitinib egfr mutations
- nsclc patients egfr mutation
- efficacy of gefitinib clinical impact
- clinical impact egfr mutations
- tkis alone egfr mutation
- nsclc patients tkis alone